Overview

Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate Gemcitabine in patients with advanced gastrointestinal (GI) or ovarian tumors (Phase I). 2. To assess response rate and survival in advanced upper GI tumors following completion of therapy (Phase II).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Department of Radiation Oncology
University of Maryland, Baltimore

Collaborator:

Eli Lilly and Company

Treatments:

Gemcitabine